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BACKGROUND. The cytokine IL-7 is critical for T cell development and function. We
performed a Phase Ib study in patients with type 1 diabetes (T1D) to evaluate how blockade
of IL-7 would affect immune cells and relevant clinical responses.
METHODS. Thirty-seven subjects with T1D received s.c. RN168, a monoclonal antibody
that blocks the IL -7 receptor a (IL7Ra) in a dose-escalating study.
RESULTS. Between 90% and 100% IL-7R occupancy and near-complete inhibition of
pSTAT5 was observed at doses of RN168 1 mg/kg every other week (Q2wk) and greater.
There was a significant decline in CD4+ and CD8+ effector and central memory T cells and
CD4+ naive cells, but there were fewer effects on CD8+ naive T cells. The ratios of Tregs to
CD4+ or CD8+ effector and central memory T cells versus baseline were increased. RNA
sequencing analysis showed downmodulation of genes associated with activation, survival,
and differentiation of T cells. Expression of the antiapoptotic protein Bcl-2 was reduced. The
majority of treatment-emergent adverse events (TEAEs) were mild and not treatment
related. Four subjects became anti–EBV IgG+ after RN168, and 2 had symptoms of active
infection. The immunologic response to tetanus toxoid was preserved at doses of 1 and 3
mg/kg Q2wk but reduced at higher doses.
CONCLUSIONS. This trial shows that, at dosages of 1–3 mg/kg, RN168 selectively inhibits
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Introduction
The cytokine IL-7 is required for the development of  T cells and lymphoid structures and is needed to 
maintain their survival and immune homeostasis (1). In particular, IL-7 is responsible for the longevity of  
CD4+ and CD8+ central and effector memory T cells (2–6). IL-7–mediated T cell survival signaling occurs 
primarily via the Jak/Stat pathway and, to a lesser extent, the PI3K pathway (7, 8). Resting naive T cells 
express high levels of  IL-7 receptor α (IL-7RA), which is rapidly downregulated once these cells are exposed 
BACKGROUND. The cytokine IL-7 is critical for T cell development and function. We performed a 
Phase Ib study in patients with type 1 diabetes (T1D) to evaluate how blockade of IL-7 would affect 
immune cells and relevant clinical responses.
METHODS. Thirty-seven subjects with T1D received s.c. RN168, a monoclonal antibody that blocks 
the IL -7 receptor α (IL7Rα) in a dose-escalating study.
RESULTS. Between 90% and 100% IL-7R occupancy and near-complete inhibition of pSTAT5 was 
observed at doses of RN168 1 mg/kg every other week (Q2wk) and greater. There was a significant 
decline in CD4+ and CD8+ effector and central memory T cells and CD4+ naive cells, but there were 
fewer effects on CD8+ naive T cells. The ratios of Tregs to CD4+ or CD8+ effector and central memory 
T cells versus baseline were increased. RNA sequencing analysis showed downmodulation of genes 
associated with activation, survival, and differentiation of T cells. Expression of the antiapoptotic 
protein Bcl-2 was reduced. The majority of treatment-emergent adverse events (TEAEs) were mild 
and not treatment related. Four subjects became anti–EBV IgG+ after RN168, and 2 had symptoms 
of active infection. The immunologic response to tetanus toxoid was preserved at doses of 1 and 3 
mg/kg Q2wk but reduced at higher doses.
CONCLUSIONS. This trial shows that, at dosages of 1–3 mg/kg, RN168 selectively inhibits the 
survival and activity of memory T cells while preserving naive T cells and Tregs. These immunologic 
effects may serve to eliminate pathologic T cells in autoimmune diseases.
TRIAL REGISTRATION. NCT02038764.
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to antigen and become effector cells. Subsequent removal of  antigen restores IL-7RA expression on T cells 
destined to become memory cells (9). IL-7RA blockade may arrest or reverse autoimmunity by attenuating 
these survival signals and depleting memory T cells, while leaving functional Tregs intact (10, 11).
Reduced expression of  IL-7RA has been seen in conditions of  chronic CD8+ T cell activation that 
occurs with autoimmunity, with chronic viral infections, and in the tumor microenvironment, and it is 
associated with functional T cell “exhaustion” (12–14). Exhausted T cells do not produce cytokines such as 
IFN-γ and IL-2, which are needed for T cell effector function (15, 16). In addition to reduced expression of  
IL-7RA, exhausted T cells show an increased expression of  inhibitory receptors such as programmed cell 
death-1 (PD-1) and lymphocyte activation gene-3 (LAG3) (13, 15, 17). Increased production of  the soluble 
form of  IL-7RA via alternative splicing is associated with increased multiple sclerosis risk (18), suggesting 
a role for IL-7RA in shared mechanisms of  autoimmunity. Indeed, improved prognoses were associated 
with reduced expression of  IL-7RA in patients with systemic lupus erythematosus, type 1 diabetes (T1D), 
antineutrophil cytoplasmic antibody vasculitis, and idiopathic pulmonary fibrosis (14).
Because of  the central role of  IL-7RA in T cell survival and function, strategies that exploit this path-
way to induce anergy, exhaustion, or apoptosis of  pathogenic T cells may have therapeutic utility in auto-
immune conditions. IL-7RA blockade may facilitate induction of  anergy or exhaustion by upregulating 
PD-1 (10) or promoting apoptosis of  autoantigen reactive T cells by downregulating anti-apoptotic B cell 
leukemia-2 (Bcl-2) molecules (e.g., Bcl-2, myeloid cell leukemia-1) (7, 8) and by triggering transcriptional 
induction of  the proapoptotic Bcl-2 family member Bcl-2–interacting mediator of  cell death (19). In the 
nonobese diabetic (NOD) mouse model of  T1D, IL-7RA blockade was shown to spare Tregs (10), which is 
consistent with their low expression of  IL-7RA.
In T1D, clinical and preclinical studies have suggested that the pathogenic β cell destruction is mediat-
ed by T cells, and preclinical studies have shown that the activity of  diabetogenic T cells is dependent on 
IL-7. In NOD mice, a preclinical model, IL-7R blocking antibodies reduced CD4+ T cell infiltration in the 
pancreas but spared Tregs, consistent with their low levels of  expression of  IL-7RA. There was increased 
expression of  PD-1 and other inhibitory signal receptors on effector T cells, leading to prevention and rever-
sal of  diabetes (10, 11, 20). In addition, observations from T cell–directed immune therapies suggest a cen-
tral role of  IL-7R signaling in the efficacy of  these agents. A recent study of  an LFA-3–Fc fusion protein, 
alefacept, as well as an FcR nonbinding anti-CD3 mAb, teplizumab, showed improved C-peptide responses 
for 2 years when patients with new-onset T1D were treated (21–23). There was decreased expression of  
IL-7R on CD8+ central memory T cells in the teplizumab-treated responders (24, 25). With alefacept, this 
is consistent with the increased expression of  IL-7R by CD2 signaling.
RN168 (PF-06342674), a humanized IgG1 monoclonal antibody (mAb), binds the human IL-7RA 
(CD127) to block IL-7–mediated signaling. Because of  the demonstrated role of  T cells and the efficacy 
of  RN168 in preclinical models, we conducted a multiple–ascending dose phase Ib trial of  RN168 in adult 
subjects with T1D to determine the safety and immunologic effects of  RN168 (26, 27). Herein, we describe 
the effects of  the drug treatment on T cell subsets, as well as the safety, tolerability, immunogenicity, and 
pharmacokinetics (PK) of  drug treatment.
Results
Study population. A total of  37 subjects were randomly assigned to dose-ascending treatment with RN168 1 
mg/kg every other week (Q2wk) × 6 doses, 3 mg/kg Q2wk × 6 doses, 8 mg/kg Q2wk × 6 doses, 6 mg/kg 
every week (QW) × 12 doses, or placebo in a double-blinded, placebo controlled (within each) cohort manner. 
Thirty-seven subjects were evaluated for pharmacodynamics (PD) and safety outcomes; there were 8, 9, 8, 
and 5 subjects in the 4 RN168 dosing groups, respectively, and 7 in the placebo group. A total of  4 subjects 
discontinued before completion of  the study (Figure 1). One subject receiving 3 mg/kg was discontinued due 
to a serious adverse event of  atrial fibrillation deemed unrelated to treatment. One subject in the 6 mg/kg QW 
group did not receive all doses of  study drug due to active Epstein-Barr virus (EBV) infection. Demographic 
characteristics of  the study population are shown in Supplemental Table 1 (supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.126054DS1).
PD and PK results. An analysis of  the serum levels of  RN168 are shown in Supplemental Figure 1 and 
Supplemental Table 2. Exposure, based on area under the curve (AUCτ) and peak concentration (Cmax), 
increased in a greater-than dose-proportional manner after multiple doses. Across all doses, and for single 
and multiple doses, absorption was slow (time to maximal concentration [Tmax] 48.9–86.3 hours), as was 
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elimination (half-life [T1/2] was 64.6 hours with RN168 3 mg/kg Q2wk, and 85.5 hour with RN168 8 mg/
kg Q2wk). Of  the 30 patients treated with RN168, 22 (73.3%) developed anti-drug antibodies, of  which 12 
(54.5%) were neutralizing; however, these antibodies had no apparent effects on PK parameters.
PD are shown in Figure 2A. RN168 doses of  3 mg/kg Q2wk, 6 mg/kg QW, and 8 mg/kg Q2wk 
decreased unbound IL-7 receptors (IL-7Rfree) on CD3
+ cells by 90%, 95%, and 100% compared with base-
line values, respectively, which was sustained until day 85 — the end of  the study drug treatment. RN168 
1 mg/kg Q2wk decreased IL-7Rfree by > 90% at day 8, but there was recovery of  IL-7Rfree beginning on day 
15. The pattern was similar on CD4+ and CD8+ T cell subsets (data not shown).
Target engagement was assessed based on inhibition of  ex vivo IL-7–induced phosphorylated STAT5 
(pSTAT5) in CD3+ T cells (Figure 2B). RN168 doses of  3 mg/kg Q2wk, 6 mg/kg QW, and 8 mg/kg Q2wk 
exhibited near complete pSTAT5 inhibition, which was sustained over the dosing period. The inhibition of  
pSTAT5 was incomplete and variable at the 1 mg/kg Q2wk RN168 dose.
Effects of  RN168 on immune cells. The changes in WBC counts and T, B, and NK cells are shown in Table 1, 
Figure 3, and Supplemental Figure 2. Total WBC and total lymphocyte counts were compared with the baseline 
levels throughout the study. The WBC counts declined within the first week of drug administration but remained 
in the normal range in all but 1 subject, who was in the 3 mg/kg group (Table 1 and Supplemental Figure 2A).
When the pooled data were analyzed with a mixed model with repeated measures and fixed effects 
for baseline levels, there was a significant decline in the naive CD4+ but not CD8+ naive T cells (P 
< 0.01 and P = 0.07, respectively) (Supplemental Table 3 and Figure 3, A and B). There was also a 
significant decline in CD4+ effector and central memory T cell populations compared with the place-
bo cohort (Figure 3, C and E) (CD4 effector memory, P = 0.001; CD4 central memory, P = 0.0007). 
Although CD8+ effector and central memory cells were also decreased (P = 0.012 and P = 0.017, 
respectively), there was greater variability compared with the CD4+ T cells (Figure 3, D and F).
There was a general increase in the frequency of  CD4+PD-1+ and CD8+PD-1+ T cells at day 85, but the 
changes in the PD-1+ cells did not reach statistical significance (Supplemental Figure 3, mixed model with 
pooled data with fixed effects for baseline values, P = 0.11 for both).
The absolute number of  Tregs declined at all doses greater than 1 mg/kg (Figure 4A). The ratio of  
Tregs to CD4+ and CD8+ effector memory T cells was increased at all doses, reaching statistical signifi-
cance at the 6 mg/kg Q2wk dose for CD4+ effector memory T cells (P = 0.04) (Figure 4, B and C; mixed 
model with repeated measures with fixed effects for baseline levels). These ratio effects were attributed 
to enhanced effects of  RN168 on reducing effector T cells (Figure 3) compared with Tregs. The relative 
Figure 1. Subject disposition. PK, pharmacokinetics; PD, pharmacodynamics; SAE, serious adverse event.
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number of  NK cells increased at doses above 1 mg/kg, but we did not observe changes in B cells (Supple-
mental Figure 2, D and E).
Effects of  RN168 on the transcriptome of  T cells. Total RNA was isolated from CD4+ and CD8+ T cells 
magnetically separated from previously frozen peripheral blood mononuclear cells (PBMC). Whole tran-
scriptome analysis of  CD4+ and CD8+ PBMC T cells was performed using RNA sequencing (RNA-seq), 
and the differences in gene expression were compared between day 85 and baseline. In CD8+ T cells, there 
were 60 downregulated and 1 upregulated protein-coding genes that showed a statistically significant change 
(paired test from DEseq2, P < 0.05) after correction for multiple comparisons. In the CD8+ cells, a pathway 
analysis identified reduced expression of  genes involved in T cell activation (CD40L), differentiation (LTK, 
KLRB1), and effector function (IL-12, GZMK) (Figure 5, C and D). In the CD4+ T cells, there were 60 down-
regulated and 3 upregulated protein-coding genes (Figure 5, A and B). Genes downregulated in CD4+ T cells 
included those associated with T cell trafficking and differentiation (CCR4, CCR6, Tbet, CXCR3). There was 
Figure 2. IL-7 receptor (IL-7R) engage-
ment by RN168 and phosphorylation of 
STAT5 in CD3+ T cells. (A) IL-7R on CD3+ 
T cells. Baseline mean (±SD) values: pla-
cebo 1899.9 (565.6) (n = 7); RN168 1 mg 
1327.7 (589.6) (n = 8); RN168 3 mg 1648.3 
(376.2) (n = 9); RN168 6 mg 2245.8 
(536.5) (n = 5); RN168 8 mg 2185.8 
(722.8) (n = 8). (B) pSTAT5 in CD3+ T 
cells. Baseline mean (±SD) values: 
placebo 3750.4 (1393.9) (n = 7); RN168 
1 mg 3681.7 (1665.7) (n = 8); RN168 3 
mg 3707.7 (1321.4) (n = 9); RN168 6 mg 
4066.0 (722.0) (n = 5); RN168 8 mg 
3877.4 (1065.5) (n = 8).
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limited overlap in the genes downregulated in CD4+ and CD8+ T cell subsets, suggesting differential effects 
of  RN168 on each cell population.
To further detail the PD effects of  RN168 on T cell gene expression profiles, the relationship between 
serum RN168 exposure expressed as the average serum levels (Cavg) and gene expression change between 
day 85 and baseline in CD8+ T cells was examined. Using this dose-response analysis, there were 220 genes 
downregulated and 80 upregulated (P < 0.01). Supplemental Table 4 shows a listing of  the changes in the 
top 50 differentially expressed genes in CD8+ T cells associated with exposure to RN168. The strongest 
relationships were between the reduced expression of  suppressor of  cytokine signaling-2 (SOCS2) and Bcl-
2, and increased expression of  cyclin dependent kinase inhibitor-2A interacting protein (CDKN2AIP), a 
protein that regulates DNA damage response (Figure 6A). Members of  the IL-7R signaling pathway were 
specifically analyzed (Supplemental Table 5 and Figure 6B). The expression of  IL-2RA (CD25, correlation 
between expression change and Cavg by linear regression, P = 0.008) and the common γ chain (P = 0.0053), 
and other transcripts associated with signaling (MAP2K2, STAT5B), showed reduced expression at higher 
Cavg. The IL-7R gene itself  showed increased gene expression at higher Cavg (CD127, P = 0.024) (Figure 6C).
To confirm our transcriptome findings, we analyzed the expression of  1 of  the affected genes, Bcl-2, in 
CD3+ T cells by flow cytometry. The protein expression was reduced overall in both CD4+ (molecules of  
equivalent soluble fluorochrome; pooled RN168 vs. placebo: mixed model with pooled data with repeated 
measures and fixed effects for baseline values, P = 0.0014; Figure 7A) and CD8+ (P = 0.008) T cells (Figure 
7B). The levels were reduced at day 85 (P = 0.0009 and P = 0.02 in CD4+ and CD8+ T cells, respectively) 
and returned to baseline values approximately 30 days after the last dose (CD8+ not shown).
Safety. Thirty-three subjects experienced 194 all-causality treatment-emergent adverse events (TEAEs) 
and were generally not dose related; the highest proportion of  TEAEs was in the placebo group (Table 2  
and Supplemental Table 6). The most common (≥4 subjects) treatment-related AEs across all groups 
were headache, hypoglycemia, fatigue, nasopharyngitis, and nausea. After receiving 8 mg/kg, 1 subject 
experienced lymphopenia to < 500/μL that remained low for greater than 2 months after the last study 
treatment. One subject in the 6 mg/kg mg/kg dose group, negative at baseline for CMV viral DNA but 
positive for IgG antibody, had detectable viral DNA on day 85 (<137 IU/mL CMV DNA), subsequently 
returning to negativity by day 127, but this subject did not have symptoms of  active CMV infection. Two 
subjects (1 each in the 6 and 8 mg/kg dose groups) seroconverted from negative EBV IgG (viral DNA 
undetectable) before treatment to positive IgG antibody at day 15 and at day 85, respectively. The subject 
receiving 6 mg/kg exhibited lymphadenopathy, splenomegaly, lethargy, and pharyngitis, and the other 
subject receiving 8 mg/kg exhibited grade 1 submandibular lymphadenopathy at days 15–57, but this 
resolved. In the subject with lymphadenopathy and splenomegaly, RN168 was discontinued for 4 weeks 
until the viral infection event resolved. Study drug was reinstated with no further incident.
RN168 was not associated with an increase compared with placebo in allergic or hypersensitivity 
reactions, hypoglycemic events, or clinically significant electrocardiogram (ECG) abnormalities. While 1 
patient had a transient alanine aminotransferase (ALT) increase > 3× upper limits of  normal (ULN), there 
were no cases meeting criteria for Hy’s Law. Mild injection-site reactions were reported by 14.3% of  the 
placebo group, and 12.5%, 11.1%, 25%, and 60% of  the RN168 1 mg/kg Q2wk, 3 mg/kg Q2wk, 8 mg/kg 
Q2wk, and 6 mg/kg QW groups, respectively.
Table 1. Effects of RN168 on WBC countsA
Parameter RN168 
1 mg/kg Q2wk  
(n = 8)
RN168 
3 mg/kg Q2wk  
(n = 9)
RN168 
8 mg/kg Q2wk  
(n = 8)
RN168 
6 mg/kg Q1wk  
(n = 5)
Placebo (n = 7)
WBC count < 0.6 × LLN 0 1 (11.1) 0 0 0
Lymphocytes < 0.8 × LLN 2 (25.0) 2 (22.2) 1 (12.5) 2 (40.0) 0
Monocytes > 1.2 × ULN 0 0 0 1 (20.0) 0
Total neutrophils > 1.2 × ULN 0 1 (11.1) 0 0 0
Total Neutrophils < 0.8 × LLN 3 (37.5) 1 (11.1) 0 2 (40.0) 1 (14.3)
ABased on absolute counts, 103/mm3, without regard for any baseline abnormality. LLN, lower limits of normal; ULN, upper limits of normal. SD in 
parentheses.
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Figure 3. Depletion of memory T cells with RN168 analyzed by flow cytometry. (A) CD4+ naive T cells. Baseline mean (±SD) values: placebo 312.588 
(127.118) (n = 7); RN168 1 mg 373.576 (139.967) (n = 8); RN168 3 mg 283.811 (146.604) (n = 9); RN168 6 mg 348.374 (135.402) (n= 5); RN168 8 mg 
359.917 (165.903) (n = 8). (B) CD8+ naive T cells. Baseline mean (±SD) values: placebo 224.313 (142.442) (n = 7); RN168 1 mg 217.871 (96.265) (n = 8); 
RN168 3 mg 1 168.591 (119.241) (n = 9); RN168 6 mg 230.688 (42.754) (n = 5); RN168 8 mg 143.347 (73.942) (n = 8). (C) CD4+ effector memory T cells. 
Baseline mean (±SD) values: placebo 78.740 (37.003) (n = 7); RN168 1 mg 61.577 (24.059) (n = 8); RN168 3 mg 51.880 (24.289) (n = 9); RN168 6 mg 
104.004 (28.278) (n = 5); RN168 8 mg 98.285 (57.377) (n = 8). (D) CD8+ effector memory. Baseline mean (±SD) values: placebo 69.043 (34.030) (n = 
7); RN168 1 mg 101.506 (39.746) (n = 8); RN168 3 mg 56.524 (34.175) (n = 9); RN168 6 mg 107.370 (64.998) (n = 5); RN168 8 mg 113.887 (102.241) (n = 
8). (E) CD4+ central memory T cells. Baseline mean (±SD) values: placebo 259.875 (57.937) (n = 7); RN168 1 mg 318.130 (161.006) (n = 8); RN168 3 mg 
326.387 (138.693) (n = 9); RN168 6 mg 440.594 (171.652) (n = 5); RN168 8 mg 367.127 (154.881) (n = 8). (F) CD8+ central memory T cells. Baseline mean 
(±SD) values: placebo 52.228 (12.748) (n = 7); RN168 1 mg 44.133 (12.803) (n = 8); RN168 3 mg 60.531 (46.720) (n = 9); RN168 6 mg 78.612 (39.220) (n 
= 5); RN168 8 mg 53.712 (61.200) (n = 8).
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Clinical responses to treatment with RN168. We analyzed C-peptide responses to a mixed meal test and pri-
mary recall responses to tetanus toxoid (Figure 8). There was little change in the C-peptide AUC C-peptide 
in either the placebo or drug-treated subjects (Figure 8A).
At the day-85 visit, 2 patients receiving placebo, 3 patients receiving 1 mg/kg Q2wk, 3 patients receiving 3 
mg/kg Q2wk, and 2 patients receiving 8 mg/kg Q2wk had an increase in C-peptide compared with baseline; 
the increased level was sustained in 1 patient receiving placebo, 1 patient in the 1 mg/kg, and 2 patients 3 mg/
kg group. We also did not detect any significant effects on hemoglobin A1C (HbA1c) levels or insulin use 
(Supplemental Figure 4, A and B).
We also determined the effects of  drug treatment on recall immune responses. The study subjects 
received a booster dose of  tetanus toxoid, and the effects of  the immunization were studied on days 29 
and 43. Primary recall response (at day 43) was reduced in participants who received the 2 higher doses of  
RN168 (χ2 = 13.7, P = 0.009) (Figure 8B). We did not find a direct relationship between a negative recall 
response and the changes in lymphocyte counts.
Discussion
The results of  this phase Ib study show that, in adult subjects with T1D, blockade of  IL-7R decreases 
memory and effector T cells, while largely not affecting Tregs. Specifically, we found reduced CD4+ and 
CD8+ T effector and memory cell numbers, but we found preservation of  the relative proportion of  Tregs. 
The expression of  genes associated with T cell activation and differentiation were modulated. Protective 
immunity to tetanus toxoid was maintained at doses < 3 mg/kg Q2wk. Our transcriptome and phenotype 
data suggest that T cell survival was reduced by starvation of  IL-7, which is needed for T cell viability and 
function. This mechanism of  action may be useful for treatment of  some T cell–based autoimmune diseas-
es in which depletion of  effector and memory T cells is desired.
Target engagement by RN168 was confirmed by a dose-dependent decrease in binding by a competitive 
antibody and by decreased IL-7–induced pSTAT5 in an ex vivo assay. These decreases were observed at 
1 mg/kg and reached a plateau at 3 mg/kg. Reductions in pSTAT5 in T cells and lower expression of  the 
Table 2. Incidence of treatment-related AEs occurring in at least 2 subjects
Treatment-related AE Incidence, n (%)
AE, MedDRA version 19.1 
preferred term
RN168 1 mg/kg Q2wk 
(n = 8)
RN168 3 mg/kg Q2wk 
(n = 9)
RN168 8 mg/kg Q2wk 
(n = 8)
RN168 6 mg/kg Q1wk 
(n = 5)
Placebo (n = 7)
Headache 2 (25.0) 2 (22.2) 3 (37.5) 0 0
Hypoglycemia 1 (12.5) 1 (11.1) 0 1 (20.0) 2 (28.6)
Fatigue 1 (12.5) 0 1 (12.5) 0 2 (28.6)
Lymphocytes decreased 1 (12.5) 0 1 (12.5) 2 (40.0) 0
Nasopharyngitis 0 0 2 (25.0) 1 (20.0) 1 (14.3)
Nausea 1 (12.5) 2 (22.2) 0 1 (20.0) 0
Cough 1 (12.5) 0 1 (12.5) 1 (20.0) 0
Diarrhea 0 0 1 (12.5) 1 (20.0) 1 (14.3)
Injection site erythema 0 0 1 (12.5) 1 (20.0) 1 (14.3)
Injection site pain 0 0 1 (12.5) 1 (20.0) 1 (14.3)
Lymphadenopathy 1 (12.5) 0 1 (12.5) 1 (20.0) 0
Oropharyngeal pain 1 (12.5) 0 1 (12.5) 1 (20.0) 0
WBC decreased 1 (12.5) 0 0 1 (20.0) 1 (14.3)
Abdominal distension 0 1 (11.1) 0 0 1 (14.3)
Hyperhidrosis 1 (12.5) 0 0 0 1 (14.3)
Injection site bruising 0 1 (11.1) 0 1 (20.0) 0
Injection site pruritus 0 0 1 (12.5) 0 1 (14.3)
Lethargy 0 1 (11.1) 0 1 (20.0) 0
Neutrophils decreased 0 0 0 1 (20.0) 1 (14.3)
Rash 1 (12.5) 0 0 0 1 (14.3)
Vomiting 0 1 (11.1) 0 0 1 (14.3)
AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; Q2wk, every other week; QW, weekly. SD in parentheses.
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anti-apoptotic protein Bcl-2 suggest inhibition of  IL-7 signaling. IL-7RA blockade in NOD mice resulted in 
PD-1 upregulation, a change that was mimicked in our human studies, although the changes did not reach 
statistical significance (10, 11).
Overall, the safety experience was acceptable and adverse events were reversible, particularly at 
doses < 6 mg/kg weekly. RN168 was well tolerated, with most treatment-related AEs considered mild 
in grade. In addition, analysis of  tetanus toxoid responses suggested that the higher doses of  the RN168 
interfered with the recall response to the vaccine. This outcome might be predicted as central memory 
CD4+ T cells, which provide help for the B cell recall response, express high levels of  CD127, and were 
thus affected by the IL-7RA blockade.
Our transcriptome studies by RNA-seq showed that the expression of  signaling molecules that are asso-
ciated with T cell survival and anti-apoptotic protein Bcl-2 were reduced. In lieu of  functional assessments, 
changes in the transcriptional profile of  isolated CD4+ and CD8+ T cells between baseline and day 85 were 
interrogated by RNA-seq. We found that key activation-related genes were downregulated in CD8+ T cells 
with RN168 treatment, including LTK, CCR4, CD40 ligand, and KLRB1, rather than genes associated with 
exhaustion in CD8+ T cells (28, 29). We suggest that these transcriptional changes may be an overall response 
to the loss of  IL-7–dependent survival signals. Unlike the transcriptional findings associated with low CD127 
expression on CD8+ T cells reported by McKinney et al. (14), we also found changes in CD4+ T cells with 
cytokine blockade, consistent with the general importance of  IL-7 generally on T cell growth and survival.
Despite the changes in effector T cells, the relative numbers of  Tregs were less affected. As a result, we 
observed a trend for increased Treg/CD4 effector T cell ratio at the 1 mg/kg Q2wk, 6 mg/kg/Q1wk, and 8 
mg/kg Q2wk doses. A change in this ratio has been suggested to result in improved immune regulation, but 
further functional studies will be needed to confirm this hypothesis (21). The increased ratio was particularly 
evident at the 1 mg/kg dose of  RN168, which may suggest that this dose is optimal. It is important to note 
that the changes that are seen were in the peripheral blood, and we cannot be certain about the effects of  the 
antibody on the relative numbers of  cells in the tissues or secondary lymph structures. Most likely, the dif-
ferential effects on Tregs and effector memory CD4+ T cells is explained by the relative importance of  IL-7 
Figure 4. Effects of RN168 on CD4+FoxP3+ Tregs assessed by 
flow cytometry. (A) Tregs. Baseline mean (±SD) values: place-
bo 44.2733 (7.5852) (n = 7); RN168 1 mg 45.7443 (22.0758) (n = 
8); RN168 3 mg 49.8629 (15.9373) (n = 9); RN168 6 mg 50.5640 
(15.3193) (n = 5); RN168 8 mg 63.3043 (31.3837) (n = 8). (B) 
Ratio of Tregs to CD4+ effector memory T cells. Baseline mean 
(±SD) values: placebo 0.650 (0.248) (n = 7); RN168 1 mg 0.776 
(0.348) (n = 8); RN168 3 mg 1.104 (0.483) (n = 9); RN168 6 mg 
0.522 (0.216) (n = 5); RN168 8 mg 0.774 (0.377) (n = 8). (C) Ratio 
of Tregs to CD8+ effector memory T cells. Baseline mean (±SD) 
values: placebo 0.931 (0.830) (n = 7); RN168 1 mg 0.588 (0.304) 
(n = 8); RN168 3 mg 1.206 (0.824) (n = 9); RN168 6 mg 0.604 
(0.321) (n = 5); RN168 8 mg 0.767 (0.655) (n = 8).
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and IL-2 as survival factors for effector T cells and Tregs, respectively. IL-7 is critical for the development 
and maintenance of  memory CD8+ T cells in mice after viral infection (3, 30) and supports antigen-specific 
expansion and effector cytokine production. In addition, IL-7 can also facilitate T cell proliferation in anti-
gen-independent mechanisms in settings such as lymphopenia, with a greater effect on CD8+ than CD4+ 
Figure 5. Gene expression changes in peripheral blood CD8+ and CD4+ T cells between day 85 and baseline in response to dosing with RN168. (A) Heat-
map of gene expression change of the top 50 differential protein-coding genes in CD4+ T cells. (B) Changes in expression of select immune-related genes 
(CCR6, RANK, Tbet, and GATA3) in CD4+ T cells. (C) Heatmap of change in expression of top 50 differentially expressed protein-coding genes in CD8+ T cells. 
(D) Changes in expression of select immune-related genes (LTK, CCR4, CD40LG, and KLRB1) in CD8+ T cells.
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T cells (31). These findings of  the Tregs/effector T cells are reminiscent of  observations with alefacept 
treatment of  patients with new-onset T1D and were thought to explain the long-term effects of  the LFA-3 
Ig treatment. The number of  NK cells were not reduced and, instead, showed an increase at higher doses. 
However, single cell transcriptome analysis in the future will be needed to resolve these differential effects on 
T cell subpopulations. It was reassuring that we did not see a decline in C-peptide, which was associated with 
increased NK cell frequency with high-dose IL-2 therapy (32).
Sufficient PBMC sampling was unavailable in this study to interrogate antigen-specific T cell activity ex 
vivo, but our functional data show that memory responses to tetanus toxoid were unaffected, except at the 
2 highest doses. Nonetheless, the reduced effector memory CD4+ and CD8+ T cells may result in reduced 
pathologic T cells that can mediate autoimmune killing of  β cells in T1D
There are limitations to our study. First, our transcriptome data were exploratory, and we did not correct for 
multiple comparisons when studying the relationship between gene expression change and drug exposure, since 
the sample size was relatively small. Additional studies with a greater number of subjects with confirmatory 
Figure 6. Dose-response analysis of 
RN168 average concentration (Cavg) 
and gene expression change between 
day 85 and baseline in CD8+ T cells. 
(A) Correlation of select individual 
genes. (B) Association of IL-2RG. (C) 
Association of IL-7R expression.
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studies will be needed. Likewise, the analysis occurred at 1 particular time point, but there may be changes in 
subsets of T cells before and after the end of therapy that are relevant to the clinical effects. We do not have infor-
mation about antigen-specific T cells, which is important both for understanding the effects on autoimmunity, 
but also on responses to latent viruses like EBV and CMV. Caution is needed in this regard, since — in addition 
to its role in survival — IL-7 and its receptor may augment cytotoxicity of CD8+ T cells, as suggested in preclin-
ical studies of transgenesis and clinical observations of augmented viral clearance correlating with IL-7 (33, 34). 
Our study was not powered to identify clinical response of IL-7RA blockade on the progression of T1D. We saw 
a decline in C-peptide in only 2 of the 6 placebo-treated subjects over the study period. It may be necessary to 
follow a larger group of subjects for longer periods of time to determine whether there are lasting clinical effects 
of treatment. Finally, it is possible that the duration of diabetes at the time of enrollment (up to 2 years after diag-
nosis), particularly with a C-peptide threshold above 0.15 pmol/mL, selected for individuals with a slow rate of  
loss of β cell function. Studies in the new-onset period are more likely to identify whether there are effects of the 
drug on the autoimmune response at a time of maximum activity.
Figure 7. Percentage change from 
baseline in Bcl-2 expression in CD3+ T 
cells. (A) CD4+Bcl-2+ T cells. Baseline 
mean (±SD) values: placebo 3231.750 
(982.634); RN168 1 mg 5973.00 (0); 
RN168 3 mg 3501.000 (507.441); RN168 
6 mg 3178.000 (702.489); RN168 8 mg 
3130.875 (1026.502). (B) CD8+Bcl-2+ T 
cells. Bcl-2 values in the RN168 1 mg/kg 
Q2wk group were unavailable after day 8 
due to an interruption in assay reagent 
availability. Baseline mean (SD) values: 
Placebo 3399.750 (1332.569); RN168 1 
mg 3218.000(0); RN168 3 mg 3434.500 
(300.684); RN168 6 mg 3217.000 
(657.476); RN168 8 mg 3255.000 
(1557.702). Placebo, n = 7; RN168 1 mg/
kgQ2wk, n = 8; RN168 3 mg/kgQ2wk, n = 
9; RN168 6 mg/kg Q1wk, n = 5; RN168 8 
mg/kg Q2wk, n = 8.
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In summary, the administration of  RN168 is safe and well tolerated, and it induces saturation and 
functional blockade of  the IL-7R, resulting in a favorable immunologic profile in T1D subjects. Memory 
and, to a lesser extent, naive T cells appear to be deleted from the peripheral blood, most likely represent-
ing the deprivation of  the IL-7 cytokine needed for their homeostasis. However, there is relative sparing 
Figure 8. Effects of RN168 on clinical 
responses. Each line represents an 
individual participant. The bold, col-
ored lines represent the mean ± SD of 
the dosing cohort. (A) C-peptide AUC 
levels. (B) Tetanus toxoid challenge, 
by treatment group. The number of 
participants in each dosing regimen 
are: placebo, n = 7; 1 mg/kg Q2wk, n = 
8; 3 mg/kd Q2wk, n = 9; 8 mg/kg, n = 
8; 6 mg/kg QW, n = 5.
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of  Tregs and an increase in the ratio of  Treg/effector T cells. This strategy may, therefore, be optimal 
for treatment of  unwanted chronic immune responses, such as in autoimmunity or transplant rejection, 
in which effector cells can be eliminated from the repertoire. Further studies to determine whether there 
is selectivity in these effects on T cell subpopulations, including effects on autoantigen-specific T cell 
clones, will be important in defining the clinical development pathway for this strategy.
Methods
Supplemental Methods are available online with this article.
Study design. This phase Ib, multicenter, double-blind (sponsor open), placebo-controlled, intracohort 
randomization, dose-escalating study (clinicaltrials.gov identifier: NCT02038764) was conducted between 
June 2014 and September 2016. The study was managed by the study sponsor (Pfizer Inc.). All study mate-
rials, including case report forms, data collection tools, and study drug, were supplied by the study sponsor. 
Eligible subjects were randomized to receive either RN168 or placebo in 4 dose cohorts consisting of  1, 3, 
and 8 mg/kg s.c. Q2wk (maximum 6 doses; cohorts 1–3) or 6 mg/kg s.c. QW (maximum 12 doses; cohort 
4) for 12 weeks, with follow-up for an additional 6 weeks. Ten subjects were randomized at an 8:2 active/
placebo ratio in each of  the first 3 dose cohorts. Five subjects were randomized 4:1 in cohort 4.
Study population. Generally healthy adults diagnosed with T1D within 2 years of  study entry with at 
least 1 T1D-related autoantibody; peak stimulated C-peptide levels ≥ 0.15 ng/mL measured during a mixed 
meal tolerance test (MMTT); and a BMI of  18.5–32 kg/m2 were enrolled. Key exclusion criteria included 
having at least 2 hospitalizations for diabetic ketoacidosis within 90 days of  randomization, HbA1c > 9%, 
severe hypoglycemia within 60 days of  randomization, and febrile illness within 24 hours of  randomization. 
Potential subjects were also excluded if  they were using diabetes medications other than insulin, had prior or 
current treatment known to change immunologic status (e.g., immune modulators), or received a recent vac-
cination with a live virus. Complete inclusion/exclusion criteria are included in the Supplemental Methods.
PD assessments. Whole blood samples were collected for receptor occupancy (RO), pSTAT5, Bcl-2+, 
T cell subsets, and PD-1+. RN168 RO samples were taken at baseline and on days 1, 3, 8, 15, 43, and 71 
(cohorts 1–3 only); 73 (cohorts 1–3 only); 78 and 80 (cohort 4 only); and 85, 92, 99, 113, and 127. Occu-
pancy of  IL-7R by RN168 in CD3+ T cells was evaluated using a competitive antibody in a flow cytometry 
assay. Target engagement was also assessed by a flow cytometry assay measuring pSTAT5 (7) in whole 
blood exposed to IL-7 ex vivo.
Analysis of  cell subsets. Absolute counts of  T cell; B cell; CD16+56+ NK cell; CD4+ and CD8+ effector mem-
ory, central memory, and naive T cell; and CD4+ Treg subsets were measured in fresh cells that were sent to a 
central lab (Covance). The Covance lab is a College of  American Pathologists/Clinical Laboratory Improve-
ment Amendments (CAP/CLIA) laboratory (CAP/CLIA certified). Naive and memory T cell phenotypes 
were determined on the basis of  staining with CD45RO, CD45RA, and CCR7: naive, CD45RA+CCR7+; 
effector, CD45RO+CCR7–; central memory, CD45RO+CCR7+. Tregs were identified as CD4+FoxP3+CD25+. 
In addition, expression of  Bcl-2 and PD-1 on CD4+ and CD8+ T cell subsets was measured by flow cytometry. 
The absolute and relative proportions of  these T cell subsets and change from baseline were calculated.
RNA-seq studies. Assessments of  immunophenotype included RNA-seq analysis of  peripheral blood 
CD4+ and CD8+ T cells isolated from PBMC preparations using magnetic bead separation. Sequence 
alignment and gene expression quantification was performed using OmicSoft ArraySuite software, version 
9.0.9.47. Transcripts per million (TPM) were generated as normalized gene expression. Subsequent analy-
sis was performed using R (version 3.4.0).
PK assessments. As detailed in the Supplemental Methods, blood samples for PK analyses were collected 
at prespecified time points through study day 127. PK parameters were calculated using noncompartmental 
analysis of  concentration-time data, with samples below the lower limit of  quantitation (i.e., <75.0 ng/mL) 
set to zero. Serum samples were also collected for analysis of  soluble (s) IL-7RA and IL-7.
Disease-related and clinical parameters. The AUC of the C-peptide response to a 4-hour MMTT was calculat-
ed from studies at screening, day 85 (end of treatment), and day 127 (final follow-up). HbA1c was measured at 
a central laboratory, and the daily use of exogenous insulin for the 3 days prior was determined by subject logs 
at the time of study visits. An 8-point glucose profile at specified days and daily insulin dose were collected.
Safety outcomes included quantitation of  TEAEs, treatment-related AEs (TRAEs), and serious AEs 
(SAEs); hypo- and hyperglycemia events; allergic or hypersensitivity reactions; drug-induced liver injury 
(DILI; potential DILI or Hy’s law cases); ECG results; laboratory abnormalities; and anti-drug antibodies. 
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Serum was collected for EBV and CMV IgG antibodies and viral DNA at baseline and on day 85 and 
the end of  the follow-up period after RN168 administration. ELISA and quantitative PCR (qPCR) technol-
ogy was used to measure antibodies and viral DNA, respectively.
To assess the effect of  RN168 on primary recall response, all subjects had blood samples for anti-teta-
nus toxoid IgG taken on day 15, after which they received tetanus toxoid vaccine or Tdap vaccine (unless 
contraindicated). Anti-tetanus toxoid IgG titers were again determined on study days 29 and 43. A positive 
response was noted when the anti-tetanus toxoid IgG titers were ≥ 2 times baseline values.
Statistics. The sample size determination of  this study was not based on statistical considerations in 
either treatment-related efficacy or safety outcomes. The planned sample size was 10 subjects per dose 
cohort (reduced to 5 subjects in cohort 4) to allow for a projected 8 treated subjects per dose. All subjects 
who received at least 1 dose were analyzed for safety. All subjects with at least 1 serum concentration of  
RN168 were included in the PK analysis population and were included in the PD population if  they had 
measurements of  relevant PD biomarkers.
SAS (v9) was used for the descriptive and summary statistics for laboratory values, biomarker analysis, 
AEs, and PK parameters. Paired 2-tailed t test was used to evaluate within-treatment comparisons, and mixed 
effect model repeat measurement (MMRM) was used to determine significance in change from baseline val-
ues. For cellular data, percentages are presented, except for Bcl-2, in which the mean fluorescence of  the 
indicated subset is shown. Analysis of  covariance was done on selected cell subsets (dependent variables) 
with day 85 as a fixed time point, treatment as the independent variable, and baseline value as the covariate. 
Differential analysis was performed on RNA-seq data using DESeq2 (v1.18.1) (35), with a design matrix 
encoding patient identity as covariate for pairwise comparison between day 85 and baseline. Linear regression 
was performed to study the relationship between gene expression change and drug exposure while adjusting 
for baseline expression. The data are presented as mean or median ± SD unless otherwise indicated.
Study approval. This study was reviewed and approved by IRBs and/or Independent Ethics Committees 
at 10 participating sites in the United States: University of  Chicago, UCSF, Yale University, Washington 
University in St. Louis, University of  Minnesota, University of  Colorado, VA San Diego Healthcare Sys-
tem, Sterling IRB, Duke University Medical Center, and University of  Massachusetts. Participants were 
not enrolled at University of  Massachusetts or Duke University. The study was conducted in compliance 
with ethical principles from the Declaration of  Helsinki and in accordance with all International Council 
for Harmonisation Good Clinical Practice Guidelines, as well as local regulatory requirements. Subjects 
provided written informed consent before any screening procedures were performed.
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